A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8179 participants.

Also called NCT01492361

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 8,179 participants (enrolled count) (from the registry)
Sponsor
Amarin Pharma Inc. (from the registry)
Registry
  • NCT NCT01492361
Main results
  • Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT Journal of the American College of Cardiology, 2019-06-11 DOI, PubMed 30898607
Other papers using this trial's data
  • Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL Circulation, 2021-11-30 DOI, PubMed 34706555, PMC8614567 In the PMC Open Access subset under CC BY.
  • Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT Journal of the American Heart Association, 2023-03-07 DOI, PubMed 36802845, PMC10111466 In the PMC Open Access subset under CC BY-NC-ND.
  • Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial Journal of the American Heart Association, 2025-03-04 DOI, PubMed 39968782, PMC12132757 In the PMC Open Access subset under CC BY.
  • Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia The New England journal of medicine, 2019-01-03 DOI, PubMed 30415628
  • Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT Journal of the American College of Cardiology, 2021-10-12 DOI, PubMed 34620410
  • Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States Journal of the American Heart Association, 2024-01-02 DOI, PubMed 38156550, PMC10863822 PubMed links an erratum for this paper. Erratum: PMID 38563378 In the PMC Open Access subset under CC BY-NC.
  • Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy Circulation, 2022-08-02 DOI, PubMed 35762321
  • Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG Circulation, 2021-12-07 DOI, PubMed 34710343
  • Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT Journal of the American Heart Association, 2022-04-05 DOI, PubMed 35377160, PMC9075460 In the PMC Open Access subset under CC BY.
  • Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction Journal of the American College of Cardiology, 2022-05-03 DOI, PubMed 35483753
  • REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States Circulation, 2020-02-04 DOI, PubMed 31707829, PMC7004453 In the PMC Open Access subset under CC BY-NC-ND.
  • Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses Circulation, 2021-01-05 DOI, PubMed 33148016, PMC7752247 In the PMC Open Access subset under CC BY-NC-ND.
  • Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI Journal of the American Heart Association, 2022-03-15 DOI, PubMed 35261279, PMC9075300 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russia, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01492361. Randomized; triple masking; primary purpose prevention. Start 2011-11 (actual); primary completion 2018-05 (actual). Results posted on 2022-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Acronym
REDUCE-IT
Condition
Cardiovascular Diseases
Intervention (Drug)
AMR101
Intervention (Drug)
Placebo
Intervention (Drug)
Statin therapy
Lead sponsor
Amarin Pharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct01492361
Content hash
1792aa68ff191347e713f75a035fd82c7deb354e80a4df3c0a53c1424f38254a